title: Bioactivity of prolactin in systemic sclerosis.
abstract: OBJECTIVE
  To evaluate basal serum prolactin (PRL) levels in systemic sclerosis (SSc) patients with different degrees of skin involvement, and investigate its relationship with some of the clinical and serological parameters of the disease.
  
  
  METHODS
  Basal serum PRL was measured in 44 SSc patients (38 F, 6 M) using a rat NB2 lymphoma line cell proliferation assay. Other parameters measured were: serum aminoterminal propeptide of type III procollagen (PIIINP) by RIA; soluble alpha interleukin-2 receptor (IL-2 sRalpha), serum intercellular adhesion molecule-1 (ICAM-1), von Willebrand factor (vWF) by ELISA; the erythrocyte sedimentation rate (ESR); and C-reactive protein (CRP). Skin and organ/system involvement were assessed according to Medsger et al.'s organ/system severity scale, and global disease activity index according to Valentini et al.
  
  
  RESULTS
  The serum PRL concentration in the SSc patients was 13.8 ng/ml (95%CI from 3.2 to 49.1 ng/ml), similar than that in control subjects (12.8 ng/nl: 95%CI 3.0 to 18.4 ng/ml). Hyperprolactinemia, defined as a level > 20 ng/ml (mean 30.9 ng/ml, median 29.3) was found in a total of 6 cases (13.6%; 95%CI 5.8 to 28%) cases: in 1 out of 6 men (16.7%; 95%CI -26% to 59%) and similarly in 5/38 women (13.2%; 95%CI 1.9% to 24.4%). No correlation was found between PRL levels and SSc subgroup (lcSSc, icSSc, dcSSc), serologial parameters, or the level of disease activity. Finally, no significant correlations were found with clinical or serological variables.
  
  
  CONCLUSIONS
  The findings confirm that mild hyperprolactinemia occurs in at subgroup of SSc patients. However, prospective studies are needed to better define the relationship between PRL and disease activity in scleroderma.
authors.affiliation: Dipartimento Scientifico di Internistica Clinica e Sperimentale F. Magrassi & A. Lanzara, Seconda Università di Napoli, Naples, Italy. giovanni.lamontagna@unina2.it
authors.forename: G
authors.initials: G
authors.lastname: La Montagna
authors.forename: R
authors.initials: R
authors.lastname: Meli
authors.forename: T
authors.initials: T
authors.lastname: Criscuolo
authors.forename: S
authors.initials: S
authors.lastname: D'Angelo
authors.forename: G
authors.initials: G
authors.lastname: Valentini
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D002455:Cell Division; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D011347:Procollagen / Q000097:blood; D011388:Prolactin / Q000097:blood*; D015375:Receptors, Interleukin-2 / Q000097:blood; D012595:Scleroderma, Systemic / Q000097:blood* / Q000473:pathology / Q000503:physiopathology; D012720:Severity of Illness Index; D012867:Skin / Q000473:pathology; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D010446:Peptide Fragments; D011347:Procollagen; D015375:Receptors, Interleukin-2; C041876:procollagen Type III-N-terminal peptide; D014841:von Willebrand Factor; D018799:Intercellular Adhesion Molecule-1; D011388:Prolactin; D002097:C-Reactive Protein